Results 51 to 60 of about 149,947 (195)

Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer

CA: A Cancer Journal for Clinicians, Volume 75, Issue 5, Page 436-460, September/October 2025.
Abstract High‐grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of all ovarian cancer cases and contributing significantly to the high mortality rates associated with this disease.
Pawel Kordowitzki, Britta Lange, Kevin M. Elias, Marcia C. Haigis, Sylvia Mechsner, Ioana Elena Braicu, Jalid Sehouli   +6 more
wiley   +1 more source

Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 Immunotherapy

Chronic Diseases and Translational Medicine, Volume 11, Issue 3, Page 173-185, September 2025.
The interaction of tislelizumab with PD‐1/PD‐L1 in the tumor microenvironment. Tislelizumab targets PD‐1 on T cells, blocking its interaction with PD‐L1 on tumor cells. This action is facilitated by a modified F(ab) region that limits Fc‐γ receptor binding, thereby enhancing the antitumor immune response. ABSTRACT Tislelizumab is a next‐generation PD‐1
Thy T. Nguyen, Bohan Zhang, Luke Zhong, Xiuyi Liang, Letao Bo   +4 more
wiley   +1 more source

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma

Cancer Science, Volume 116, Issue 8, Page 2189-2197, August 2025.
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara, Isao Yoshida, Takuro Ishiguro, Katsuya Fujimoto, Junya Kuroda, Toshiki Uchida, Ryusuke Yamamoto, Yoshiaki Ogawa, Yasushi Hiramatsu, Toshiro Ito, Seiichiro Katagiri, Tomonori Nakazato, Kazumi Suzukawa, Kenzo Kinami, Mi Zhou, Eiju Negoro   +15 more
wiley   +1 more source

An Observational Retrospective Analysis to Study the Clinical and Epidemiological Aspects of Severe Cutaneous Adverse Drug Reactions

Journal of Marine Medical Society
Background: Severe cutaneous adverse reactions (SCARs) are rare but potentially life-threatening conditions leading to significant morbidity and mortality.
Surg Cdr Padmapriya Srinivasan, Lt Col Veena Kharayat, Surg Cdr Reetu Agarwal, Maj Anil Kumar, Surg Cmde Sridhar Jandhyala, Surg Cdr Bhavni Oberoi, Surg Cdr (retd) Manish Khandare   +6 more
doaj   +1 more source

Clinical Presentation and Diagnosis of Multisystemic Eosinophilic Epitheliotropic Disease in a Miniature Donkey: A Case Report

Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.
ABSTRACT A 21‐year‐old miniature donkey gelding was evaluated for pruritus, inappetence, hypertriglyceridemia, and alopecia of 2 weeks' duration. Hematology showed moderate eosinophilia, severe hypertriglyceridemia, and moderately increased liver enzyme activities. Cytologic evaluation of peritoneal fluid identified an eosinophilic transudate.
Carla K. Enriquez, Alicia E. Long, Cristobal Navas de Solis, Perry L. Habecker, Rose Nolen‐Walston   +4 more
wiley   +1 more source

Erythroderma : Review of a potentially life -threatening dermatosis

Indian Journal of Dermatology, 2009
Erythroderma, or generalized exfoliative dermatitis, is a disease characterized by erythema and scaling of greater than 90% of the body′s surface. The resultant dysmetabolism is potentially life threatening.
Okoduwa Cynthia, Lambert W, Schwartz R, Kubeyinje E, Eitokpah A, Sinha Smeeta, Chen W   +6 more
doaj  

Perils with Pirfenidone and “the tuberculosis link”

International Journal of Mycobacteriology, 2019
We report a case of idiopathic pulmonary fibrosis (IPF) treated with pirfenidone who developed tuberculosis (TB) and later had exfoliative dermatitis secondary to an interaction between pirfenidone and rifampicin. This case report highlights the possible
Madhav H Hande, K Vishak Acharya, A Shreenivasa, Kashinath Nayak, S Arun   +4 more
doaj   +1 more source

Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report

Cancer Reports, Volume 8, Issue 6, June 2025.
ABSTRACT Background Imatinib treatment is approved for several indications, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Although adverse events are common, hypersensitivity reactions are not. Because there is a clear clinical benefit of imatinib treatment, re‐introduction of imatinib after a hypersensitivity ...
Maud B. A. van der Kleij, Tristan V. M. Bruijn, Raween W. Kalicharan, Yannick S. Elshot, Maxime C. F. Pilon, Mark Oostdijk, Matthijs M. Tibben, Bastiaan Nuijen, Alwin D. R. Huitema, Thomas Rustemeyer, Neeltje Steeghs   +10 more
wiley   +1 more source

Erythrodermic Psoriasis with Superimposed Fungal Infection-a Presentation in the Emergency Room

Eurasian Journal of Emergency Medicine, 2018
Erythrodermic psoriasis or erythroderma is a life-threatening, generalized exfoliative dermatitis involving majority of the body surface. A detailed evaluation is required for the identification of its underlying cause to successfully treat and prevent ...
Muhammad Akbar Baig, Sadaf Sheikh
doaj   +1 more source

Pemphigus foliaceus: A rare case of exfoliative dermatitis

Clinical Dermatology Review, 2017
Exfoliative dermatitis (ED) is a dermatological condition necessitating admission as it can sometimes be fatal because of its metabolic burden and complications. Papulosquamous disorders and drug reactions comprise over 75% of all the causes of ED.
Vaishnavi Gopal, Malcolm Pinto, Manjunath Shenoy Mala   +2 more
doaj   +1 more source